Margarete Mehrabian

Title: Margarete Mehrabian: Innovator in Atherosclerosis Research

Introduction

Margarete Mehrabian is a prominent inventor based in Sherman Oaks, CA (US). She has made significant contributions to the field of atherosclerosis research, particularly through her innovative work on the gene 5-lipoxygenase (5-LO). Her research has implications for understanding cardiovascular diseases and their genetic underpinnings.

Latest Patents

Margarete Mehrabian holds a patent for the identification of 5-lipoxygenase as a major gene contributing to atherosclerosis. This patent highlights the expression of 5-LO in monocyte/macrophages and foam cells within atherosclerotic lesions. It also discusses the differential expression of this gene in various mouse models, revealing that mice heterozygous for a null mutation of 5-LO exhibit dramatically reduced atherosclerosis compared to control mice. Furthermore, her research indicates a strong association between a common 5-LO polymorphism and carotid artery intima-media thickness in coronary artery disease patients. These findings underscore the role of 5-LO and the leukotriene biosynthetic pathway in atherogenesis.

Career Highlights

Margarete Mehrabian is affiliated with the University of California, where she continues her research and innovation in the field of genetics and cardiovascular health. Her work has garnered attention for its potential to influence treatment strategies for atherosclerosis and related conditions.

Collaborations

Margarete has collaborated with notable researchers such as Aldons J Lusis and Hooman Allayee. These partnerships have enriched her research and expanded the impact of her findings in the scientific community.

Conclusion

Margarete Mehrabian's contributions to the understanding of atherosclerosis through her patent on 5-lipoxygenase exemplify the vital role of innovation in medical research. Her work continues to pave the way for advancements in cardiovascular health.